Researchers at the University of Michigan Medical School have developed a map of the United States highlighting significant variation in stroke care.
Researchers at the University of Michigan Medical School have developed a quilted map of the United States highlighting the tremendous variation in stroke care in need of standardization. Published this month in the journal Stroke, the study points to the huge variation in the use of the "clotbuster" drug tissue plasminogen activator (tPA), which if administered within the first few hours of a stoke can restore blood supply to the brain. This can avoid potential disabilities and lower long-term costs of care in the patients.
The population used in the study were Medicare enrollees who had suffered from a stroke and were admitted through Emergency Rooms in one of 3436 hositals surveyed in the study between 2007 and 2010. In 20% of the geographical regions where these hospitals were located, patients did not receive tPA. Of the 844,241 admissions resulting from ischemic stroke, 3.7% of patients were administered tPA and only 0.5% received intra-arterial stroke treatment, with or without tPA.
A senior author on the study believes understanding the causes of the variation and addressing them would have a significant impact on stroke-associated disability.
Read more on EurekAlert!
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More